HIF2 is responsible for NSCLC transformation. This effect occurs in the lung epithelium and the surrounding microenvironment. EMT transcription factors are enhanced by hypoxia EMT promoting ...

Non-small-cell lung cancer (NSCLC) treatment has led to improved efficacy and compliance due to individual tailoring of the therapeutic options and the use of strategies based on both clinical ...

Once non-small-cell lung cancer (NSCLC) spreads far and wide, treating it is kind of a balancing act. A cure isn't likely, but you can slow it down. So you aim to relieve your symptoms and improve ...

Bristol Myers Squibb (BMS) has secured another win for Opdivo (nivolumab), becoming the only FDA-approved PD-1 inhibitor for resectable non-small cell lung cancer NSCLC in both a neoadjuvant-only ...

Deferring CNS-directed radiation therapy in EGFR-variant and ALK-positive NSCLC with brain metastases improves outcomes but increases treatment-related toxicity. Up-front stereotactic radiosurgery ...

At ASCO, Eli Lilly, Genfleet Therapeutics and InxMed all presented new clinical data on KRAS G12C inhibitors in non-small cell lung cancer (NSCLC), going after the same mutation and indication as ...

Adagrasib and pembrolizumab combination therapy achieved a median PFS of 27.7 months in KRASG12C-mutated NSCLC patients with PD-L1 ≥50%. The combination therapy showed a 59.3% overall response ...